Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3.

Chen WS, Cao Z, Sugaya S, Lopez MJ, Sendra VG, Laver N, Leffler H, Nilsson UJ, Fu J, Song J, Xia L, Hamrah P, Panjwani N.

Nat Commun. 2016 Apr 12;7:11302. doi: 10.1038/ncomms11302.

2.

Canonical and noncanonical vascular endothelial growth factor pathways: new developments in biology and signal transduction.

Domigan CK, Ziyad S, Iruela-Arispe ML.

Arterioscler Thromb Vasc Biol. 2015 Jan;35(1):30-9. doi: 10.1161/ATVBAHA.114.303215. Review.

3.

Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway.

Yu J, Zhang X, Kuzontkoski PM, Jiang S, Zhu W, Li DY, Groopman JE.

Cell Commun Signal. 2014 Apr 7;12:25. doi: 10.1186/1478-811X-12-25.

4.

Interactions between VEGFR and Notch signaling pathways in endothelial and neural cells.

Thomas JL, Baker K, Han J, Calvo C, Nurmi H, Eichmann AC, Alitalo K.

Cell Mol Life Sci. 2013 May;70(10):1779-92. doi: 10.1007/s00018-013-1312-6. Review.

5.

Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitro.

Iwasaki T, Takeda Y, Maruyama K, Yokosaki Y, Tsujino K, Tetsumoto S, Kuhara H, Nakanishi K, Otani Y, Jin Y, Kohmo S, Hirata H, Takahashi R, Suzuki M, Inoue K, Nagatomo I, Goya S, Kijima T, Kumagai T, Tachibana I, Kawase I, Kumanogoh A.

J Biol Chem. 2013 Jan 25;288(4):2118-31. doi: 10.1074/jbc.M112.424291.

6.
7.

Slit2/Robo4 signaling modulates HIV-1 gp120-induced lymphatic hyperpermeability.

Zhang X, Yu J, Kuzontkoski PM, Zhu W, Li DY, Groopman JE.

PLoS Pathog. 2012 Jan;8(1):e1002461. doi: 10.1371/journal.ppat.1002461. Erratum in: PLoS Pathog. 2012 Jul;8(7): doi/10.1371/annotation/5af1d62a-8262-4340-ad06-c450a50295e3.

8.

Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke.

Baeten KM, Akassoglou K.

Dev Neurobiol. 2011 Nov;71(11):1018-39. doi: 10.1002/dneu.20954. Review.

9.

Combined blockade of VEGFR-3 and VLA-1 markedly promotes high-risk corneal transplant survival.

Zhang H, Grimaldo S, Yuen D, Chen L.

Invest Ophthalmol Vis Sci. 2011 Aug 17;52(9):6529-35. doi: 10.1167/iovs.11-7454.

10.

Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator.

Zhang X, Maor Y, Wang JF, Kunos G, Groopman JE.

Br J Pharmacol. 2010 Aug;160(7):1583-94. doi: 10.1111/j.1476-5381.2010.00841.x.

11.

Novel aspects of corneal angiogenic and lymphangiogenic privilege.

Ellenberg D, Azar DT, Hallak JA, Tobaigy F, Han KY, Jain S, Zhou Z, Chang JH.

Prog Retin Eye Res. 2010 May;29(3):208-48. doi: 10.1016/j.preteyeres.2010.01.002. Review.

12.

Lymphangiogenesis and lymphatic metastasis in breast cancer.

Ran S, Volk L, Hall K, Flister MJ.

Pathophysiology. 2010 Sep;17(4):229-51. doi: 10.1016/j.pathophys.2009.11.003.

13.
14.

Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis.

Somanath PR, Malinin NL, Byzova TV.

Angiogenesis. 2009;12(2):177-85. doi: 10.1007/s10456-009-9141-9. Review.

15.

Integrin and growth factor receptor alliance in angiogenesis.

Somanath PR, Ciocea A, Byzova TV.

Cell Biochem Biophys. 2009;53(2):53-64. doi: 10.1007/s12013-008-9040-5. Review.

16.

Lymphatics in lung disease.

El-Chemaly S, Levine SJ, Moss J.

Ann N Y Acad Sci. 2008;1131:195-202. doi: 10.1196/annals.1413.017. Review.

17.

Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism.

Wijelath ES, Rahman S, Namekata M, Murray J, Nishimura T, Mostafavi-Pour Z, Patel Y, Suda Y, Humphries MJ, Sobel M.

Circ Res. 2006 Oct 13;99(8):853-60.

18.

Lymphangiogenic growth factor responsiveness is modulated by postnatal lymphatic vessel maturation.

Karpanen T, Wirzenius M, Mäkinen T, Veikkola T, Haisma HJ, Achen MG, Stacker SA, Pytowski B, Ylä-Herttuala S, Alitalo K.

Am J Pathol. 2006 Aug;169(2):708-18.

19.

Supplemental Content

Support Center